| Literature DB >> 19274101 |
Ambreen Ansari1, Najeeha Talat, Bushra Jamil, Zahra Hasan, Tashmeem Razzaki, Ghaffar Dawood, Rabia Hussain.
Abstract
BACKGROUND: Pakistan ranks 7(th) globally in terms of tuberculosis (TB) disease burden (incidence 181/100000 pop./yr; prevalence of 329/pop./yr). Reports from different populations show variable associations of TB susceptibility and severity with cytokine gene polymorphisms. Tuberculosis clinical severity is multi-factorial and cytokines play a pivotal role in the modulation of disease severity. We have recently reported that the ratio of two key cytokines (IFNgamma and IL10) show significant correlation with the severity spectrum of tuberculosis. The objective of the current study was to analyze the frequency of cytokine gene polymorphisms linked to high and low responder phenotypes (IFNgamma +874 T(hi)-->A(lo) and IL10 -1082 G(lo)-->A(hi)) in tuberculosis patients. METHODS ANDEntities:
Mesh:
Substances:
Year: 2009 PMID: 19274101 PMCID: PMC2652824 DOI: 10.1371/journal.pone.0004778
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic characteristics of TB Patients and Controls.
| Group Studied | N | Gender | Age (years) | ||
| Female (%) | Male (%) | Mean | Range | ||
| TB not affected controls (TBNA) | 188 | 88 (46.8) | 100 (53.1) | 28.10 | 6–70 |
| TB affected patients (TBA) | 188 | 118 (62.7) | 70 (37.2) | 33.40 | 7–81 |
|
| 111 | 65 (58.5) | 46 (41.4) | 32.0 | 10–81 |
| Pulmonary minimal (PMN) | 19 | 9 (47.3) | 10 (52.6) | 36.3 | 15–81 |
| Pulmonary moderate (PMD) | 63 | 37 (58.7) | 26 (41.2) | 33.0 | 13–70 |
| Pulmonary advance (PAD) | 29 | 19 (65.5) | 10 (34.4) | 26.2 | 10–69 |
|
| 67 | 47 (70.1) | 20 (35.0) | 34.5 | 7–80 |
| Disseminated TB (DTB) | 20 | 12 (60.0) | 8 (40.0) | 37.3 | 16–80 |
| Localized TB (LTB) | 47 | 35 (74.5) | 12 (25.5) | 33.3 | 7–75 |
Note: Patient stratification is as given in Materials and Methods. Abbreviations for groups are given in brackets. TBA included 10 previously treated patients.
Figure 1Relationship of IFNγ and IL10 SNPs with mycobacterial antigen induced cytokine secretion.
Whole blood from TB not affected (TBNA) Tuberculin skin test positive donors was stimulated with M. tuberculosis culture filtrate (CF) proteins [5 µg/ml] and supernatants tested at 2 days for IL10 secretion and day 5 for IFNγ secretion using ELISA method as described in material and methods. Results are expressed as pg/ml after deducting secretion in un-stimulated whole blood.
Genotype frequencies in healthy controls and different clinical forms of tuberculosis (TB).
| Genotypes | TBNA (188) | TBA (188) | PTB (111) | PMN (19) | PMD (63) | PAD (29) | ETB (67) | DTB (20) | LTB (47) |
|
| |||||||||
|
| 25 (13.3) | 39 (20.74) | 27 (24.32) | 8 (42.11) | 16 (25.4) | 3 (10.34) | 12 (17.91) | 3 (15.00) | 9 (19.15) |
|
| 87 (46.28) | 83 (44.15) | 47 (42.34) | 6 (31.58) | 28 (44.44) | 13 (44.83) | 30 (44.78) | 8 (40.00) | 22 (46.80) |
|
| 76 (40.43) | 66 (35.11) | 37 (33.33) | 5 (26.32) | 19 (30.16) | 13 (44.83) | 25 (37.31) | 9 (45.00) | 16 (34.04) |
|
| 3.86 | 6.05 | 10.69 | 5.58 | 0.30 | 0.87 | 0.29 | 1.28 | |
|
| 0.08 |
|
|
| 0.588 | 0.433 | 0.859 | 0.278 | |
|
|
| 0.064 |
|
|
| 0.780 | 0.649 | 0.857 | 0.495 |
|
| |||||||||
|
| 20 (10.64) | 27(14.36) | 19 (17.12) | 4 (21.05) | 7 (11.1) | 8 (27.59) | 8 (11.94) | 4 (20.00) | 4 (8.51) |
|
| 136 (72.34) | 132 (70.21) | 71 (63.96) | 11 (57.893) | 46(73.02) | 14 (48.25) | 51 (76.12) | 12 (60.00) | 39 (82.98) |
|
| 32 (17.02) | 29 (15.43) | 21 (18.92) | 4 (21.05) | 10 (15.89) | 7 (24.14) | 8 (11.94) | 4 (20.00) | 4 (8.51) |
|
| 1.25 | 3.09 | 2.20 | 0.05 | 8.41 | 0.98 | 1.85 | 2.52 | |
|
| 0.33 | 0.489 | 0.621 | 0.831 | 0.374 | 0.384 | 0.612 | 0.437 | |
|
|
| 0.435 | 0.767 | 0.945 | 0.867 | 0.341 | 0.330 | 0.582 | 0.357 |
Note: Patient stratification is given in Materials and Methods. N for each group given in brackets. Abbreviations used as in Table 1. Number (frequency) of genotypes is indicated. Pearson chi analysis was carried to determine the significance of differences.
All significant p values are indicated in bold. P approaching significance is given in italics. p<0.05 is considered significant.
Differences in allele frequencies in healthy controls and tuberculosis patients
| IFN-γ (+874 Thi→Alo) | N | chi-value | corrected | OR | 95% CI (lower) | 95% CI (upper) |
|
|
| |||||
|
|
| 3.20 | 0.074 | 1.31 | 0.79 | 1.75 |
|
|
| 4.78 |
| 1.46 | 1.04 | 2.04 |
|
|
| 6.72 |
| 2.4 | 1.22 | 4.72 |
|
|
| 4.95 |
| 1.59 | 1.05 | 2.38 |
|
|
| 0.29 | 0.587 | 0.85 | 0.47 | 1.53 |
|
|
| 0.46 | 0.50 | 1.15 | 0.77 | 1.72 |
|
|
| 0.032 | 0.858 | 0.94 | 0.47 | 1.86 |
|
|
| 1.12 | 0.274 | 1.29 | 0.82 | 2.05 |
|
| ||||||
|
|
| |||||
|
|
| 0.53 | 0.48 | 1.11 | 0.83 | 1.48 |
|
|
| 0.29 | 0.58 | 1.01 | 0.79 | 1.54 |
|
|
| 0.14 | 0.708 | 1.14 | 0.58 | 2.22 |
|
|
| 0.025 | 0.875 | 1.03 | 0.69 | 1.55 |
|
|
| 0.49 | 0.486 | 1.22 | 0.7 | 2.12 |
|
|
| 0.036 | 0.85 | 1.04 | 0.7 | 1.54 |
|
|
| 0.15 | 0.701 | 1.14 | 0.59 | 2.18 |
|
|
| 0.307 | 0.58 | 1.14 | 0.72 | 1.79 |
Note: Patient stratification is given in material and methods. N for each group is given in brackets. Abbreviations used as in Table 1.
Genotype combination in relation to disease severity.
| IFNγ/IL10 genotypes | TBNA | PMN | PMD | PAD | DTB | LTB |
| N | 188 | 19 | 63 | 29 | 20 | 47 |
|
| 2.13 | 10.53 | 1.59 | 6.9 | 0 | 4.2 |
| chi2 | 6.66 | |||||
|
|
| |||||
|
|
| |||||
|
|
| |||||
|
| 3.19 | 10.53 | 6.35 | 3.45 | 5 | 2.13 |
| chi2 | 4.92 | |||||
|
|
| |||||
|
|
| |||||
|
|
| |||||
|
| 7.98 | 21.05 | 17.46 | 0 | 10 | 12.8 |
| chi2 | 6.82 | 4.4 | ||||
|
|
|
| ||||
| OR |
|
| ||||
| (95% CI) |
|
| ||||
|
| 5.85 | 0 | 4.76 | 6.9 | 10 | 2.13 |
| chi2 | ||||||
|
| ||||||
|
| ||||||
|
| 5.32 | 10.53 | 6.35 | 6.9 | 0 | 4.2 |
| chi2 | ||||||
|
| ||||||
|
| ||||||
|
| 35.11 | 21.05 | 33.33 | 31.03 | 30 | 40.4 |
| chi2 ( | 4.86 | |||||
|
|
| |||||
|
|
| |||||
|
|
| |||||
|
| 2.66 | 10.53 | 4.76 | 13.79 | 10 | 2.13 |
| chi2 | 4.92 | 7.78 | 4.03 | |||
|
|
|
|
| |||
|
|
|
|
| |||
|
|
|
|
| |||
|
| 8.51 | 0 | 3.17 | 13.79 | 15 | 2.13 |
| chi2 | 4.71 | |||||
|
|
| |||||
|
|
| |||||
|
|
| |||||
|
| 39.26 | 15.79 | 22.2 | 17.24 | 20 | 29.7 |
| chi2 | 4.85 | 4.06 | ||||
|
|
|
| ||||
|
|
|
| ||||
|
|
|
|
Diagnostic modality used for confirmation of tuberculosis.
| Disease | N | % (TST≥10 mm) | Microscopy | Culture | Histology |
| Response to treatment |
| TBNA | 188 | 71 | - | - | - | - | - |
| Pulmonary | 111 | 62 | 47 | 24 | 0 | 38 | 2 |
| Disseminated | 20 | 35 | 1 | 3 | 2 | 12 | 2 |
| Localized | 47 | 43 | 1 | 10 | 13 | 10 | 13 |
Note: Primary diagnostic modality used diagnosis of tuberculosis.
Criteria for disease category given in material and methods.
Imaging tests included chest×rays for pulmonary patients, CT scan and or MRI for disseminated disease.